nusinersen


( Last Updated : November 4, 2021)
Generic Name:
nusinersen
Project Status:
Pending
Therapeutic Area:
Spinal Muscular Atrophy
Manufacturer:
Biogen Canada Inc.
Call for patient/clinician input open:
Brand Name:
Spinraza
Project Line:
Reimbursement Review
Project Number:
SR0713-000
Call for patient/clinician input closed:

Details


Manufacturer Requested Reimbursement Criteria1:
Biogen Canada Inc. requests that the previous CADTH-recommended criteria (see project SR0576-000) for Spinraza be expanded to include adult type II & type III patients older than 18 years of age regardless of ambulatory status.
Submission Type:
Reassessment
Fee Schedule:
Pending
Indications:
Spinraza (nusinersen) is indicated for the treatment of 5q Spinal Muscular Atrophy (SMA).
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.